<DOC>
	<DOCNO>NCT00629837</DOCNO>
	<brief_summary>The primary objective study determine pharmacokinetic profile single administration two dos BAY 79-4980 ( high low : 35 IU FVIII/Kg reconstitute 22 mg 13 mg liposomes/Kg , respectively ) compare rFVIII-FS ( 35 IU/Kg reconstitute 2.5 mL WFI/1000 IU ) PTPs age 12 60 year severe hemophilia A .</brief_summary>
	<brief_title>Pharmacokinetics Safety Single Intravenous Infusion BAY 79-4980</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males age 12 60 year Hemophilia A plasma FVIII level le 1 % ( severe hemophilia ) No history FVIII inhibitor antibody formation current evidence inhibitor antibody measure use Nijmegen modify Bethesda assay ( &lt; 0.6 Nijmegen Bethesda Units [ N.B.U . ] /mL ) No sign symptom acute bleed episode day infusion Four day without treatment FVIII prior day infusion Subject ( subject 's legal representative ) must provide write informed consent authorization use disclosure Protected Health Information ( PHI ) Subjects must previously treat FVIII concentrate total least 200 exposure day , include 20 exposure day previous 12 month . Previous treatment type rFVIII plasmaderived FVIII concentrate Individuals abnormal renal function ( serum creatinine concentration great 1.3 mg/dL ) active hepatic disease ( persistent aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] increase great five time upper limit normal ) . Individuals anemia , define hemoglobin level less 12 g/dL Any individual past history severe reaction ( ) FVIII product Any individual interferon treatment receive interferon within previous 3 month Any individual thrombocytopenia ( platelet great equal 100,000 cells/mm3 ) know hematologic/bleeding problem hemophilia A Any individual receiving receive experimental drug within 3 month prior study entry Any individual know dislipidemic disease actively take cholesterol lower drug treatment hypercholesterolemia hyperlipidemia ( e.g. , statin , cholesterol absorption inhibitor , bile acid sequestrants , nicotinic acid fibrates ) individual take anaesthetic drug Any individual require premedication FVIII infusion ( e.g. , antihistamine ) Any individual high blood pressure ( define diastolic blood pressure great equal 100 mm/Hg ) Any patient forego FVIII treatment least 4 day prior study entry study infusion due need frequent prophylactic treatment preexist medical condition Any patient know allergy severe reaction liposomes PEG Individuals known disease affect hemostasis besides hemophilia A Any patient suitable participation trial reason , accord Investigator</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>FVIII</keyword>
	<keyword>Long act</keyword>
	<keyword>pk</keyword>
</DOC>